GSK-3β Inhibitor XII, TWS119, The GSK-3β Inhibitor XII, TWS119, also referenced under CAS 601514-19-6, controls the biological activity of GSK-3β. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
A cell-permeable and potent inhibitor of GSK-3β (IC50 = 30 nM). Binds to GSK-3β with high-affinity (Kd = 126 nM), leading to an increase in the level of β-catenin, a downstream substrate of GSK-3β in the Wnt signaling pathway. Shown to selectively induce neuronal differentiation in both pluripotent murine embryonal carcinoma cells (P19; 30-40% at 1 µM) and embryonic stem cells (D3; 50-60% at 400 nM).
A cell-permeable pyrrolopyrimidine compound that acts as a potent inhibitor of GSK-3β (IC50 = 30 nM). Binds to GSK-3β with high-affinity (Kd = 126 nM) and increases the level of β-catenin, a downstream substrate of GSK-3β in the Wnt signaling pathway. Shown to selectively induce neuronal differentiation in both pluripotent murine embryonal carcinoma cells (P19; 30-40% at 1 µM) and embryonic stem cells (D3; 50-60% at 400 nM).
Biochem/physiol Actions
Cell permeable: yes
Kd = 126 nM against GSK-3β
Primary Target GSK-3β
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Warning
Toxicity: Carcinogenic / Teratogenic (D)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Ding, S., et al. 2003. Proc. Natl. Acad. Sci. USA100, 7632.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Cancer immunology research, 11(2), 171-183 (2022-12-10)
Vα24-invariant natural killer T cells (NKT) possess innate antitumor properties that can be exploited for cancer immunotherapy. We have shown previously that the CD62L+ central memory-like subset of these cells drives the in vivo antitumor activity of NKTs, but molecular
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
